Zura Bio(NASDAQ) ZURA

Zura Bio Limited makes drugs for people with painful immune diseases. These medicines help patients when other treatments fail to work. The company is testing its products in medical studies right now.

The Medicine Cabinet

• Tibulizumab (ZB-106): Dual-acting treatment for skin and tissue diseases like hidradenitis suppurativa and systemic sclerosis.
• Torudokimab (ZB-880): Monoclonal antibody targeting proteins that cause lung and airway inflammation.
• Crebankitug (ZB-168): Experimental drug that blocks specific signals in the immune system to treat inflammatory conditions.

Strategic Licensing and Growth

• Acquired rights to develop and commercialize tibulizumab through a 2023 license agreement with Lilly.
• Entered a license agreement with Pfizer in March 2022 to develop and market crebankitug.
• Secured a license for torudokimab from Lilly in December 2022 to target inflammatory signaling pathways.
• Raised $134.6 million in net proceeds from a public stock offering in February 2026.

Developing New Solutions

Zura licenses its drug candidates from established global pharmaceutical leaders to focus on molecules with existing research. This strategy allows the company to advance through clinical trials without starting from the earliest research stages.

By the Numbers

• Net loss was $50.5 million for the six months ended June 30, 2026, up 51% year over year.
• Research and development expenses reached $35.4 million for the six months ended June 30, 2026, up 85% year over year.
• Cash and cash equivalents totaled $205.1 million as of June 30, 2026.
• Accumulated deficit reached $275.1 million as of June 30, 2026.

Zura Bio's Journey

Zura has grown into a clinical-stage biotechnology firm with multiple active Phase 2 trials for autoimmune diseases. Its focus remains on licensing and testing therapies to meet significant unmet medical needs.